Insider Selling: Relay Therapeutics (NASDAQ:RLAY) CFO Sells 972 Shares of Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 972 shares of the business’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $14.79, for a total transaction of $14,375.88. Following the transaction, the chief financial officer owned 212,895 shares in the company, valued at approximately $3,148,717.05. This trade represents a 0.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Thomas Catinazzo also recently made the following trade(s):

• On Tuesday, April 7th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The stock was sold at an average price of $13.01, for a total transaction of $230,498.17.
• On Thursday, April 9th, Thomas Catinazzo sold 1,800 shares of Relay Therapeutics stock. The stock was sold at an average price of $15.00, for a total transaction of $27,000.00.

Relay Therapeutics Stock Up 3.1%

Relay Therapeutics stock traded up $0.39 during midday trading on Thursday, hitting $12.96. 2,389,616 shares of the stock were exchanged, compared to its average volume of 2,773,398. Relay Therapeutics, Inc. has a 52-week low of $2.67 and a 52-week high of $17.32. The stock has a market capitalization of $2.32 billion, a price-to-earnings ratio of -8.00 and a beta of 1.57. The business’s 50-day moving average price is $11.79 and its 200-day moving average price is $9.10.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.06. The firm had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $4.34 million. On average, sell-side analysts predict that Relay Therapeutics, Inc. will post -1.51 earnings per share for the current fiscal year.

Institutional Trading of Relay Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of RLAY. AQR Capital Management LLC raised its position in shares of Relay Therapeutics by 11.9% in the first quarter. AQR Capital Management LLC now owns 364,946 shares of the company’s stock valued at $956,000 after purchasing an additional 38,812 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Relay Therapeutics by 6.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,069 shares of the company’s stock valued at $221,000 after purchasing an additional 5,238 shares during the period. Millennium Management LLC increased its position in shares of Relay Therapeutics by 14.6% during the first quarter. Millennium Management LLC now owns 2,942,875 shares of the company’s stock valued at $7,710,000 after buying an additional 374,491 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Relay Therapeutics during the first quarter valued at about $53,000. Finally, Woodline Partners LP lifted its holdings in shares of Relay Therapeutics by 448.4% in the first quarter. Woodline Partners LP now owns 1,518,561 shares of the company’s stock worth $3,979,000 after buying an additional 1,241,657 shares in the last quarter. Institutional investors own 96.98% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on RLAY. Citizens Jmp lifted their price objective on shares of Relay Therapeutics from $17.00 to $19.00 and gave the stock a “market outperform” rating in a research report on Tuesday. JonesTrading began coverage on shares of Relay Therapeutics in a research report on Tuesday, April 14th. They issued a “hold” rating and a $18.00 price objective on the stock. HC Wainwright lifted their price objective on shares of Relay Therapeutics from $19.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday. Wells Fargo & Company lifted their price objective on shares of Relay Therapeutics from $17.00 to $21.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, Oppenheimer lifted their price objective on shares of Relay Therapeutics from $14.00 to $18.00 and gave the stock an “outperform” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $20.56.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.